13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | $22M | 76.7% | 31.2% | $17M | — | $51M |
| 2024 | $73M | $19M | 76.9% | 30.0% | $18M | — | $52M |
| 2023 | $66M | $17M | 76.5% | 30.6% | $6M | — | $50M |
| 2022 | $53M | $13M | 77.4% | 29.3% | $9M | — | $58M |
| 2021 | $42M | $9M | 76.6% | 23.5% | $11M | — | $62M |
| 2020 | $32M | $1M | 74.3% | -2.4% | $5M | — | $50M |
| 2019 | $39M | $10M | 77.1% | 22.5% | $10M | — | $43M |
| 2018 | $30M | $6M | 76.3% | 19.7% | $7M | — | $28M |
| 2017 | $23M | $499764 | 75.9% | 5.6% | $3M | — | $18M |
| 2016 | $32M | $7M | 81.1% | 33.6% | $9M | — | $18M |
| 2015 | — | $8M | — | — | $7M | — | $19M |
| 2014 | — | $2M | — | — | — | — | $9M |
| 2013 | — | $2M | — | — | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $22M | $6M | 76.5% | 32.9% | $8M | — | $56M |
| Dec '25 | $23M | $6M | 75.1% | 31.3% | $6M | — | $51M |
| Sep '25 | $21M | $6M | 77.8% | 32.2% | $6M | — | $57M |
| Jun '25 | $20M | $6M | 78.2% | 33.3% | $5M | — | $53M |
| Mar '25 | $20M | $5M | 76.1% | 27.8% | $595000 | — | $50M |
| Dec '24 | $19M | $5M | 76.1% | 29.9% | $3M | — | $52M |
| Sep '24 | $18M | $5M | 77.4% | 31.6% | $5M | — | $52M |
| Jun '24 | $18M | $5M | 78.1% | 31.4% | $6M | — | $49M |
| Mar '24 | $18M | $4M | 76.1% | 27.0% | $4M | — | $45M |
| Dec '23 | $17M | $5M | 76.9% | 29.6% | $3M | — | $50M |
| Sep '23 | $17M | $5M | 77.8% | 35.8% | $1M | — | $47M |
| Jun '23 | $16M | $4M | 75.5% | 30.8% | $3M | — | $46M |
| Mar '23 | $15M | $3M | 75.7% | 25.9% | -$2M | — | $43M |
| Dec '22 | $15M | $4M | 75.5% | 28.6% | $3M | — | $58M |
| Sep '22 | $13M | $3M | 78.6% | 30.8% | $4M | — | $56M |
| Jun '22 | $13M | $3M | 79.7% | 32.8% | $1M | — | $52M |
| Mar '22 | $12M | $2M | 76.2% | 25.0% | $1M | — | $50M |
| Dec '21 | $12M | $4M | 77.9% | 26.2% | $3M | — | $62M |
| Sep '21 | $11M | $3M | 77.1% | 28.3% | $3M | — | $58M |
| Jun '21 | $10M | $1M | 74.7% | 18.8% | $3M | — | $55M |
How the market has priced IRMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Iradimed Corp's revenue has grown 21.5% per year, and net income grown 75.0% per year. These are computed facts, not advice.
As of FY2025, Iradimed Corp reported — of total debt against $51M of cash.
In FY2025, gross margin was 76.7%, operating margin 31.2%, and net margin 26.8%.
As of Jun '26, Iradimed Corp traded at a price-to-earnings ratio of about 53.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.